AB Science's masitinib meets in mastocytosis study

AB Science S.A. (Euronext:AB) said masitinib ( AB1010) met the primary objective of a Phase III study to treat severe systemic mastocytosis.

The 135-patient, placebo-controlled trial evaluated response rate between week eight and week 24. A response was defined as an improvement of at least 75% in mastocytosis symptoms over baseline. ...